Active Ingredient History

  • Now
Istradefylline is a first-in-class adenosine A2A receptor antagonist antiparkinsonian agent and has been marketed as the brand name NOURIAST® in Japan since May 30, 2013. NOURIAST is indicated for the improvement of wearing-off phenomena in patients with Parkinson’s disease on concomitant treatment with levodopa-containing products.   NCATS

  • SMILES: CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
  • Mol. Mass: 384.429
  • ALogP: 2.12
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$36.6513 - $36.6691
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1h-purine-2,6-dione | istradefylline | kw6002 | kw 6002 | kw-6002 | nouriast


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue